GeneDx Holdings Corp. (WGS)

From the record

GeneDx Holdings Corp.'s filings since 2020 show 7 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2022-12-30); a warning not to rely on past financial statements (8-K item 4.02, 3 times, the latest 2022-03-14); an auditor change (8-K item 4.01, 2 times, the latest 2021-08-16); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-05-18) (its current reports).

From the record

GeneDx Holdings Corp.'s 7 filed years say what it did: revenue went from $196 million in fiscal 2019 to $428 million in fiscal 2025, up 13.9% a year; it rose in 4 of 6 years; the deepest fall was 14% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, GeneDx Holdings Corp. lost about 7 cents for every dollar of shareholders' money, and gross profitability: its products earned about 57 cents per dollar of everything the company owns. Leverage: it owed about 41 cents per dollar of assets, and net share issuance: its share count grew 6.5% over the year (the filed statements).

From the record

GeneDx Holdings Corp.'s standing among 14 graded names in its industry family: revenue of $428 million in fiscal 2025 ranks in the top 46% by size; a net margin of -4.9% ranks in the bottom 39%; revenue growth of 22.1% a year over the last 3 filed years ranks in the top 32% (its annual reports).

From the record

GeneDx Holdings Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Stueland, Katherine (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2022-05-02, 4.5 years (top 15% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 4.5 years (bottom 32%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

GeneDx Holdings Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $105 million against debt of $48 million leaves 10.8% of its assets as net cash, top 46% of its family; cash from operations less capital spending is 3.3% of revenue (bottom 39%); a gross margin of 69.7% (top 6%); research spending of 16.8% of revenue (top 10%) (its annual report).

From the record

GeneDx Holdings Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 22.1% a year over the last three filed years against 13.9% over all 7, speeding up (top 11% of its family); the newest year grew 40% (top 25%); research spending grew -5.8% a year (top 50%); capital spending grew 38.5% a year (top 35%) (its annual reports). GeneDx Holdings Corp. reported 2 lines of business in fiscal 2025: Gene Dx at $423 million (99%), All Other at $4 million (1%); 2 of 2 grew against the year before (its annual report).

From the record

GeneDx Holdings Corp.'s newest year against its own record: revenue of $428 million in fiscal 2025 came in 22.7% above the $348 million its prior three years' pace pointed to (top 29% of its family); net income of $21 million against a prior three-year average of $259 million (top 46%); a net margin of -4.9% against losses larger than its revenue before (top 12%) (its annual reports).